Obesity Abstracts

With the global increase in obesity and diabetes, the use of weight negative therapy, such as the glucagon-like peptide -1 receptor agonists (GLP-1 RA) are increasing. The most common side effects with the GLP-1RA are gastrointestinal symptoms, mainly nausea. Other common adverse effects include headache, injection site reactions, and are usually minor and do not result in cessation of therapy. GLP-1RA are also associated with slowed gastric emptying, by virtue of their mode o...